| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2000;36:127.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
Bradykinin B2 Receptor Gene Polymorphism Is Associated With Angiotensin-Converting Enzyme Inhibitor–Related Cough
From the Third Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan.
Correspondence to Shuji Mukae, MD, Third Department of Internal Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.
Abstract—The appearance of cough in association with angiotensin-converting enzyme (ACE) inhibitors is thought to be related to bradykinin, and it has been speculated that the elicitation of adverse effects is genetically predetermined. Several polymorphisms of the human bradykinin B2 receptor gene may be involved in ACE inhibitor–related cough. To investigate this possibility, we identified the -58 thymine (T)/cytosine (C) polymorphism in subjects with ACE inhibitor–related cough. We classified the study population into 4 groups: subjects with and without cough that were treated with ACE inhibitors (n=30/30), nontreated essential hypertensive subjects (n=100), and normotensive subjects (n=100). The -58T/C was genotyped by the polymerase chain reaction single-strand conformation polymorphism method. The frequencies of the CC genotype and C allele of -58T/C were significantly higher in the nontreated hypertensive subjects than in the normotensive subjects. Conversely, the frequencies of the TT genotype and T allele were significantly higher in the subjects with cough than in the subjects without cough. These tendencies were more pronounced in females. Among the promoter assays of the human bradykinin B2 receptor, -58T was found to have a higher transcription rate than that of -58C. This finding seems to suggest that the transcriptional activity of promoter might be involved in the appearance of ACE inhibitor–related cough. A genetic variant of the bradykinin receptor is involved in the elicitation of ACE inhibitor–related cough. It may be possible to predict the side effects of ACE inhibitors in advance.
Key Words: bradykinin • genes • polymorphism • promoter
This article has been cited by other articles:
 |
|
 |
|
  H-K Park, S-Y Oh, T-B Kim, J-W Bahn, E-S Shin, J-E Lee, H-B Oh, Y-K Kim, T Park, S-H Cho, et al. Association of genetic variations in neurokinin-2 receptor with enhanced cough sensitivity to capsaicin in chronic cough Thorax, December 1, 2006; 61(12): 1070 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. V. Dicpinigaitis Angiotensin-Converting Enzyme Inhibitor-Induced Cough: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 169S - 173S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. L Ripley Valsartan in Chronic Heart Failure Ann. Pharmacother., March 1, 2005; 39(3): 460 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M G Belvisi and P Geppetti Cough * 7: Current and future drugs for the treatment of chronic cough Thorax, May 1, 2004; 59(5): 438 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, J. F. Carlquist, B. D. Home, and J. B. Muhlestein Cardiovascular Pharmacogenomics: Current Status, Future Prospects Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 71 - 83. [Abstract] [PDF]
|
|
|
|
 |
|
 W. E. Evans and H. L. McLeod Pharmacogenomics -- Drug Disposition, Drug Targets, and Side Effects N. Engl. J. Med., February 6, 2003; 348(6): 538 - 549. [Full Text] [PDF]
|
|